NEW YORK, Aug. 8 – Lexicon Genetics said on Wednesday that Bristol-Myers Squibb has chosen certain drug targets from Lexicon’s LexVision library of mouse gene knockout data to move into drug development.
The drug giant's decision is significant, Lexicon Chief Financial Officer Julia Gregory told GenomeWeb , because it is the first time a subscriber to the database has identified particularly promising drug targets.
Last fall, Bristol-Myers signed on to a three- to five-year contract, potentially worth $25 million, to access LexVision and a library of mouse embryonic stem-cell clones called OmniBank. In June, Incyte Genomics became the second subscriber to LexVision.
Gregory said that because the collaboration with Bristol-Myers began only last fall, the pharmaceutical company's selection of drug targets "speaks extremely well of the caliber of information we have in LexVision on the phenotypes of our gene knockouts."
"Our whole goal is to be looking at medically relevant genes out of the entire genome so this also underscores the value of our technology in finding medically relevant genes," she added.
Bristol-Myers does not pay Lexicon for choosing drug targets from LexVision, but will make milestone and royalty payments if the target develops into a commercial product, Lexicon said.
The LexVision database includes physiological data from gene-knockout experiments in mice, including measurements of whole blood cell count, X-rays, MRI and CT scans, and certain neurological tests.